Tu My To
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Tu My To has a total of 62 co-authors. Here are the top co-authors by number of shared publications:
- William Bruce Wong
Genentech, Inc., South San Francisco, CA
19 shared publications - Stacey Kowal
Genentech, Inc., United States
18 shared publications - James D. Chambers
The Center for the Evaluation of Value and Risk in Health, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, MA
17 shared publications - Anisha M. Patel
Genentech, Inc., South San Francisco, CA USA
2 shared publications Jamie T. Ta
Genentech Inc, South San Francisco, CA, USA
2 shared publications- Matthew J. Matasar
Division of Blood Disorders, Rutgers University, New Brunswick, NJ
2 shared publications
Latest Publications
- Open Access
- 23 January 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S7 from Real-World Clinical Oncology Outcomes Associated with the Accelerated Approval Pathway
Table S7. Baseline patient characteristics among those with mUC
- 23 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S7 from Real-World Clinical Oncology Outcomes Associated with the Accelerated Approval Pathway
Table S7. Baseline patient characteristics among those with mUC
- Open Access
- 23 January 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S8 from Real-World Clinical Oncology Outcomes Associated with the Accelerated Approval Pathway
Table S8. Baseline patient characteristics among those with SCLC
- 23 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S8 from Real-World Clinical Oncology Outcomes Associated with the Accelerated Approval Pathway
Table S8. Baseline patient characteristics among those with SCLC
- Open Access
- 23 January 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S4 from Real-World Clinical Oncology Outcomes Associated with the Accelerated Approval Pathway
Table S4. Baseline patient characteristics among those with aNSCLC
- 23 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S4 from Real-World Clinical Oncology Outcomes Associated with the Accelerated Approval Pathway
Table S4. Baseline patient characteristics among those with aNSCLC
- Open Access
- 23 January 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Real-World Clinical Oncology Outcomes Associated with the Accelerated Approval Pathway
Table S2. Indication-specific inclusion criteria for analysis of outcomes of AA drugs in oncology solid tumors
- 23 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Real-World Clinical Oncology Outcomes Associated with the Accelerated Approval Pathway
Table S2. Indication-specific inclusion criteria for analysis of outcomes of AA drugs in oncology solid tumors
- Open Access
- 23 January 2026
- Published by American Association for Cancer Research (AACR)
Table 3 from Real-World Clinical Oncology Outcomes Associated with the Accelerated Approval Pathway
Patient and population outcomes during AA window for drugs in oncology solid tumors.
- 23 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable 3 from Real-World Clinical Oncology Outcomes Associated with the Accelerated Approval Pathway
Patient and population outcomes during AA window for drugs in oncology solid tumors.
- Open Access
- 23 January 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S9 from Real-World Clinical Oncology Outcomes Associated with the Accelerated Approval Pathway
Table S9. Unweighted risk of progression or death and risk of death for AA drugs vs SoC
- 23 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S9 from Real-World Clinical Oncology Outcomes Associated with the Accelerated Approval Pathway
Table S9. Unweighted risk of progression or death and risk of death for AA drugs vs SoC
- Open Access
- 23 January 2026
- Published by American Association for Cancer Research (AACR)
Table 2 from Real-World Clinical Oncology Outcomes Associated with the Accelerated Approval Pathway
Comparison of real-world evidence findings and FDA decisions for oncology solid tumors.a
- 23 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable 2 from Real-World Clinical Oncology Outcomes Associated with the Accelerated Approval Pathway
Comparison of real-world evidence findings and FDA decisions for oncology solid tumors.a
- Open Access
- 23 January 2026
- Published by American Association for Cancer Research (AACR)
Data from Real-World Clinical Oncology Outcomes Associated with the Accelerated Approval Pathway
The accelerated approval (AA) pathway expedites treatment access for patients with unmet medical needs. However, evidence on the program’s impact is lacking. This study assessed real-world clinical outcomes for AA drugs in solid tumor cancers. A nationwide electronic health record (EHR)-derived deidentified database was utilized to explore the impact of the AA pathway in patients with selected solid tumors from 2011 to 2023. Included patients received AA or non-AA products with the same indication. Outcomes were real-world progression-free survival (rwPFS) and overall survival (OS). Population-level health impacts were estimated via market share and real-world progression-free life years (rwPFLYs) and life years (LYs). Twenty-three AA indications were studied. At study completion, 83% of indications had their clinical benefit verified, whereas 17% had been withdrawn from the market. Overall, 78% of indications demonstrated significant improvements in rwPFS or OS, whereas none reported significantly worse rwPFS versus controls. In total, 44% and 48% of indications had >30% rwPFS and OS improvement, respectively. More indications with sample sizes >100 in the AA cohort demonstrated significant rwPFS gains [80% (12/15)] versus cohorts <100 [38% (3/8)]. An estimated 118,107 patients received AA drugs during their AA window, resulting in 56,399 rwPFLYs and 50,848 LYs gained. Most solid tumor AA indications were associated with improved clinical outcomes, providing substantial US population-level health gains. This EHR analysis provides insight into whether the AA pathway appropriately targets promising beneficial therapies. Expanding beyond randomized controlled trial evidence and conventional primary endpoints may be necessary to verify clinical benefit, particularly in rare tumors.Significance:This study (the first examining the real-world outcomes associated with the AA period) found improved clinical outcomes for most AA drugs studied compared with existing treatments in solid tumor cancers. The improvements observed suggest potential health improvements at the US population level and the possibility of the need to look beyond randomized controlled evidence and traditional primary endpoints to verify the clinical benefit of AA drugs for relatively rare conditions.
- 23 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from Real-World Clinical Oncology Outcomes Associated with the Accelerated Approval Pathway
The accelerated approval (AA) pathway expedites treatment access for patients with unmet medical needs. However, evidence on the program’s impact is lacking. This study assessed real-world clinical outcomes for AA drugs in solid tumor cancers. A nationwide electronic health record (EHR)-derived deidentified database was utilized to explore the impact of the AA pathway in patients with selected solid tumors from 2011 to 2023. Included patients received AA or non-AA products with the same indication. Outcomes were real-world progression-free survival (rwPFS) and overall survival (OS). Population-level health impacts were estimated via market share and real-world progression-free life years (rwPFLYs) and life years (LYs). Twenty-three AA indications were studied. At study completion, 83% of indications had their clinical benefit verified, whereas 17% had been withdrawn from the market. Overall, 78% of indications demonstrated significant improvements in rwPFS or OS, whereas none reported significantly worse rwPFS versus controls. In total, 44% and 48% of indications had >30% rwPFS and OS improvement, respectively. More indications with sample sizes >100 in the AA cohort demonstrated significant rwPFS gains [80% (12/15)] versus cohorts <100 [38% (3/8)]. An estimated 118,107 patients received AA drugs during their AA window, resulting in 56,399 rwPFLYs and 50,848 LYs gained. Most solid tumor AA indications were associated with improved clinical outcomes, providing substantial US population-level health gains. This EHR analysis provides insight into whether the AA pathway appropriately targets promising beneficial therapies. Expanding beyond randomized controlled trial evidence and conventional primary endpoints may be necessary to verify clinical benefit, particularly in rare tumors.Significance:This study (the first examining the real-world outcomes associated with the AA period) found improved clinical outcomes for most AA drugs studied compared with existing treatments in solid tumor cancers. The improvements observed suggest potential health improvements at the US population level and the possibility of the need to look beyond randomized controlled evidence and traditional primary endpoints to verify the clinical benefit of AA drugs for relatively rare conditions.
- Open Access
- 23 January 2026
- Published by American Association for Cancer Research (AACR)
Figure 1 from Real-World Clinical Oncology Outcomes Associated with the Accelerated Approval Pathway
Flow diagram of the study selection process for AA drugs in oncology solid tumors.
- 23 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 1 from Real-World Clinical Oncology Outcomes Associated with the Accelerated Approval Pathway
Flow diagram of the study selection process for AA drugs in oncology solid tumors.
- Open Access
- 23 January 2026
- Published by American Association for Cancer Research (AACR)
Table 1 from Real-World Clinical Oncology Outcomes Associated with the Accelerated Approval Pathway
Summary of AA drugs in oncology solid tumors included for real-world analysis.
- 23 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable 1 from Real-World Clinical Oncology Outcomes Associated with the Accelerated Approval Pathway
Summary of AA drugs in oncology solid tumors included for real-world analysis.